Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancerMarcos Aurélio Fonseca Magalhães, Auro del Giglio, Pedro Nazareth Aguiar et al.|Einstein (São Paulo)|2022Cited by 8